Veru Inc.
VERU
NASDAQ·Healthcare·Biotechnology·Mkt cap $42.4M
$2.64
▼ -0.38%
P/E
-3.83
Mkt Cap
$42.4M
52-Wk Range
$2.05–$7.33
52-Week Range
$2.05 - $7.33
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 21.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta -1.2).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-12.0% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying VERU right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 26, 2026
AUG 10, 2026
Reported EPS of -$0.30 vs -$0.32 consensus (+6.3% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+6.3%
Revenue trend · last 3Q
—
—
—
Q1 26
Q2 26
Q3 26
$0
$0
$0
Margins · last 3Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Oppenheimer · May 15, 2026
vs Industry
How VERU stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.